使用警語:中文譯文來源為 AI 翻譯,僅供參考,實際內容請以英文原文為主
Operator
Operator
As a reminder, this call is being recorded. Please proceed.
提醒您,本次電話會議正在錄音。請繼續。
William Brent Turner - President
William Brent Turner - President
Good morning. I'm Brent Turner, President of Acadia Healthcare, and I'd like to welcome you to our second quarter 2018 conference call.
早安。我是 Acadia Healthcare 總裁 Brent Turner,歡迎各位參加我們 2018 年第二季電話法說會。
To the extent any non-GAAP financial measure is discussed in today's call, you will also find a reconciliation of that measure to the most directly comparable financial measure calculated according to GAAP on our website by viewing yesterday's news release under the Investors link.
若今日電話會議中討論到任何非 GAAP 財務衡量指標,您也可在我們網站上,透過「投資人」連結查看昨日新聞稿,找到該指標與依 GAAP 計算之最直接可比財務衡量指標的調節表。
This conference call may contain forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995, including statements, among others, regarding Acadia's expected quarterly and annual financial performance for 2018 and beyond.
本次電話會議可能包含《1995 年私人證券訴訟改革法》所定義的前瞻性陳述,其中包括但不限於關於 Acadia 對 2018 年及其後預期之季度與年度財務表現的陳述。
For this purpose, any statements made during the call that are not statements of historical fact may be deemed to be forward-looking statements. Without limiting the foregoing, the words believes, anticipates, plans and expects and similar expressions are intended to identify forward-looking statements.
就此而言,本次電話會議中任何非歷史事實之陳述,均可能被視為前瞻性陳述。在不限制前述內容之前提下,「相信」、「預期」、「計畫」、「期望」及類似用語旨在辨識前瞻性陳述。
You are hereby cautioned that these statements may be affected by the important factors, among others, set forth in Acadia's filings with the Securities and Exchange Commission and in the company's second quarter news release. And consequently, actual operations and results may differ materially from the results discussed in the forward-looking statements. The company undertakes no obligation to update publicly any forward-looking statements whether as a result of new information, future events or otherwise.
特此提醒您,這些陳述可能受到若干重要因素影響(其中包括但不限於)Acadia 向美國證券交易委員會提交之文件以及公司第二季新聞稿中所載因素。因此,實際營運與結果可能與前瞻性陳述中討論之結果存在重大差異。公司不承擔公開更新任何前瞻性陳述之義務,不論係因新資訊、未來事件或其他原因所致。
At this time for opening remarks, I'll now turn the conference over to our Chairman and Chief Executive Officer, Joey Jacobs.
現在進入開場致詞,我將把電話會議交給我們的董事長兼執行長 Joey Jacobs。
Joey A. Jacobs - Chairman & CEO
Joey A. Jacobs - Chairman & CEO
Good morning, and thank you for being with us today for our second quarter conference call. In addition to Brent, I'm here today with our Chief Financial Officer, David Duckworth, and other members of our executive management team. David and I each have some remarks about the second quarter and our outlook for going forward in 2018, then we'll open the line for your questions.
早安,感謝各位今天參加我們的第二季電話會議。除了 Brent 之外,今天與我一同出席的還有我們的財務長 David Duckworth,以及其他執行管理團隊成員。David 和我將分別就第二季表現與 2018 年後續展望做一些說明,之後我們將開放提問。
Acadia produced solid growth of 7% in revenue and 6.1% in adjusted EPS for the second quarter. Our revenue growth continued to be driven primarily by organic growth, including a 5.2% increase in total same facility for the quarter. This growth was mainly the result of adding 889 beds to our operations over the last 12 months, including an 88-bed facility opened in the second quarter through our joint venture with Erlanger Health System in Chattanooga, Tennessee. We added 155 beds during the second quarter and 276 in the first half of the year, and we expect to add more than 800 beds to existing facilities and new facilities in 2018.
Acadia 第二季營收穩健成長 7%,調整後每股盈餘(EPS)成長 6.1%。我們的營收成長仍主要由內生成長所帶動,其中包括本季同店(同一設施)總計成長 5.2%。此成長主要來自過去 12 個月我們營運新增 889 張床位,其中包括第二季透過與田納西州查塔努加的 Erlanger Health System 合資所開設的一家 88 床機構。我們在第二季新增 155 張床位、上半年合計新增 276 張床位,並預期 2018 年在既有與新設機構合計新增超過 800 張床位。
Our 5.2% total same facility revenue growth included a 1.7% increase in patient days and a 3.4% increase in revenue per patient day. U.S. same facility revenue increased 5% for the quarter, with a 1.9% increase in patient days and a 3.1% increase in revenue per patient day. U.S. same facility EBITDA margin declined 30 basis points, 28.1%.
我們同店總營收成長 5.2%,其中包含病人日(patient days)增加 1.7%,以及每病人日營收增加 3.4%。美國同店營收本季增加 5%,其中病人日增加 1.9%,每病人日營收增加 3.1%。美國同店 EBITDA 利潤率下滑 30 個基點至 28.1%。
Our operations in the U.K. produced their best same facility growth in 2 years, with an increase in same facility revenue of 5.6%, consisting of a 1.6% increase in patient days and a 3.9% increase in revenue per patient day. Same facility EBITDA margin declined 110 basis points to 21.3 for the quarter. We expect continued pressure on labor costs due to the shortage of available personnel and reliance on agency labor.
我們在英國的營運創下近兩年最佳同店成長,同店營收增加 5.6%,其中病人日增加 1.6%,每病人日營收增加 3.9%。同店 EBITDA 利潤率本季下滑 110 個基點至 21.3。由於可用人力短缺以及對派遣人力的依賴,我們預期人力成本將持續承壓。
Thanks for your time this morning and your interest in Acadia. Now here's David Duckworth to discuss our financial results and increased guidance in more detail.
感謝各位今早撥冗以及對 Acadia 的關注。接下來請 David Duckworth 更詳細說明我們的財務結果與上調後的財測指引。
David M. Duckworth - CFO, CAO & Controller
David M. Duckworth - CFO, CAO & Controller
Thanks, Joey, and good morning. The company's revenue for the second quarter of 2018 was $765.7 million, an increase of 7% from $715.9 million for the second quarter of 2017. Adjusted earnings per diluted share increased to $0.70 for the second quarter of 2018, up 6.1% from $0.66 for the second quarter last year. Adjusted EPS excludes transaction-related expenses of $2.9 million for the second quarter of 2018 and $9.1 million for the second quarter of 2017 as well as debt extinguishment cost of approximately $800,000 for the second quarter of 2017.
謝謝你,Joey,早安。公司 2018 年第二季營收為 7.657 億美元,較 2017 年第二季的 7.159 億美元成長 7%。2018 年第二季稀釋後每股調整後盈餘增至 0.70 美元,較去年同期的 0.66 美元成長 6.1%。調整後 EPS 排除 2018 年第二季 290 萬美元與 2017 年第二季 910 萬美元的交易相關費用,以及 2017 年第二季約 80 萬美元的債務清償成本。
Acadia's tax rate on adjusted income before income taxes was 15.2% for the second quarter of 2018 compared with 24.8% for the second quarter of 2017. We project an effective tax rate of approximately 16% for the remainder of 2018.
Acadia 2018 年第二季調整後稅前所得的稅率為 15.2%,相較 2017 年第二季為 24.8%。我們預估 2018 年剩餘期間的有效稅率約為 16%。
The company's consolidated adjusted EBITDA for the second quarter of 2018 was $165 million or 21.5% of revenue. Acadia's operating cash flows from continuing operations increased 10.9% to $145.2 million for the second quarter of 2018 from $131 million for the second quarter of 2017.
公司 2018 年第二季合併調整後 EBITDA 為 1.65 億美元,占營收比重為 21.5%。Acadia 來自持續營運的營業活動現金流量在 2018 年第二季增加 10.9% 至 1.452 億美元,高於 2017 年第二季的 1.31 億美元。
Turning to our financial guidance and as announced in yesterday afternoon's news release, we have adjusted our 2018 financial guidance based on the recent decline in the U.S. dollar-to-British pound sterling exchange rate as well as the impact of higher interest rates than anticipated for the second half of 2018. We expect an exchange rate of $1.30 per British pound sterling and interest expense to be approximately $95 million for the second half of the year.
接著談我們的財測指引。如同昨天下午新聞稿所宣布,我們已根據近期美元兌英鎊匯率下跌,以及 2018 年下半年利率高於原先預期的影響,調整了 2018 年財務指引。我們預期匯率為每 1 英鎊 1.30 美元,且下半年利息費用約為 9,500 萬美元。
Our guidance is as follows: revenue in the range of $3,020,000,000 to $3,060,000,000, adjusted EBITDA in a range of $632 million to $639 million and adjusted diluted EPS in a range of $2.52 to $2.56. Our financial guidance does not include the impact from any future acquisitions and transaction-related expenses.
我們的指引如下:營收介於 30.20 億至 30.60 億美元;調整後 EBITDA 介於 6.32 億至 6.39 億美元;調整後稀釋 EPS 介於 2.52 至 2.56 美元。我們的財務指引未包含任何未來併購及交易相關費用的影響。
This concludes our prepared remarks this morning, and thank you for being with us. I'll now ask Sylvia to open the floor for your questions.
以上為我們今早的預先準備發言,感謝各位與會。接下來我將請 Sylvia 開放現場提問。
Operator
Operator
(Operator Instructions) We'll take our first person from the queue, Brian Tanquilut from Jefferies.
(接線員指示) 我們將先請隊列中的第一位提問者,Jefferies 的 Brian Tanquilut。
Brian Gil Tanquilut - Equity Analyst
Brian Gil Tanquilut - Equity Analyst
Joey, first question for you. So as I think about the organic growth here in the U.S. and how that has seemed to have decelerated a little bit, how would you explain the disconnect between that and the organic bed adds that you've done over the last 12 to 24 months? And I understand that's JVs and de novos. I just want to hear how you're thinking about that and when do you think the organic bed adds rate will catch up with your reported organic volume growth?
Joey,我的第一個問題想請教你。當我思考美國這邊的內生成長,以及看起來似乎有些放緩時,你會如何解釋這與你們在過去 12 到 24 個月所做的內生床位新增之間的落差?我理解那包含合資(JV)與新設(de novo)。我想聽聽你如何看待這件事,以及你認為內生床位新增的速度何時會追上你們所揭露的內生量(volume)成長?
Joey A. Jacobs - Chairman & CEO
Joey A. Jacobs - Chairman & CEO
Brian, thanks for the question. I expect in the third quarter in the U.S. that our patient day growth will be above 2% and approaching 3% growth if the trends today continue. We had a few facilities in the first and second quarter that hurt our growth there, but they are improving as we speak. So I think the patient day growth could very well -- I expect patient day growth to be in the 2% to 3% range for the third quarter. And -- but as you know, we are always careful about the month of August. That is the most seasonal month for us. But right now, it looks like we would be into the mid-2s on patient day growth and look forward to that. So the de novos, we have 4 of those that are ramping up as we -- and joint ventures are ramping up as we speak. So those things are going well, and we just had a few facilities that hurt us in the second quarter.
Brian,謝謝你的提問。我預期在美國第三季,如果目前的趨勢持續,我們的病人日(patient day)成長將高於2%,並接近3%的成長。第一季和第二季我們有幾家機構拖累了那邊的成長,但它們目前正在改善中。所以我認為病人日成長很可能——我預期第三季的病人日成長會落在2%到3%的區間。而且——但如你所知,我們對8月一向很謹慎。那是我們最具季節性的月份。但就目前看起來,病人日成長應該會在2%中段左右,我們也期待如此。至於新設(de novo),我們有4個正在爬坡中——合資案也正在同步爬坡。所以這些進展都不錯,只是第二季有幾家機構對我們造成了影響。
Brian Gil Tanquilut - Equity Analyst
Brian Gil Tanquilut - Equity Analyst
Got it. And then, Joey, the follow-up for me. As I think about free cash flow, you had good free cash flow generation during the quarter. How are you thinking about deployment of that? I mean, does it make sense to pay down some debt at this point and think of that as the strategy given the sort of lack of M&A activity? Or do you think that you have deals coming up that you have to save the cash for, for the next few quarters?
了解。接著,Joey,我這邊的追問。談到自由現金流,你們本季的自由現金流創造表現不錯。你們打算如何運用這些資金?我的意思是,考量目前併購活動相對不多,現在是否適合先償還部分債務,並把這當作策略?或者你認為接下來幾季會有交易出現,因此需要把現金留著以備使用?
Joey A. Jacobs - Chairman & CEO
Joey A. Jacobs - Chairman & CEO
The pipeline is very active, and we would just continue to hold the cash. I expect that by the time we talk to you again at the end of October that we would have spent some of this cash on an acquisition.
我們的案源管線非常活躍,我們會繼續保留現金。我預期等到10月底我們再與各位溝通時,我們應該已經把部分現金用在一項收購上了。
Operator
Operator
And now we'll take our next person from the queue, Peter Costa from Wells Fargo Securities.
接下來我們將從等候隊列中請下一位提問者:Wells Fargo Securities 的 Peter Costa。
Peter Heinz Costa - MD and Senior Analyst
Peter Heinz Costa - MD and Senior Analyst
Your admissions in the U.S. and the U.K. actually both looked reasonably good, but your average length of stay continued to see pressure and seemed like there was more pressure this quarter. Can you describe what caused the increase in pressure on length of stay this quarter relative to the first quarter in both the U.S. and the U.K.?
你們在美國與英國的收治入院(admissions)看起來其實都相當不錯,但平均住院天數(average length of stay)仍持續承壓,而且本季似乎壓力更大。你能否說明,相較於第一季,為何本季在美國與英國的住院天數壓力會增加?
Joey A. Jacobs - Chairman & CEO
Joey A. Jacobs - Chairman & CEO
The -- it is really just a mix change, of where in the U.S. we're having more acute patients versus the RT and specialty patients. It's a mix issue that's just driving that math. In the U.K., if you notice that their numbers are so small and their length of stay is so long that it only takes a handful of admissions or discharges to impact that number. So here in the U.S., it was just purely mix. And then in the U.K., the numbers are so small there, and because the length of stay is so high, it doesn't take a lot of movement there to make that happen. We are, in the U.K., retrofitting some beds to take on a different type of patient that would have a long length of stay as compared to the U.S. but a shorter length of stay as compared to their average overall.
這——主要就是組合變化(mix change):在美國,我們急性期病患相對增加,而相較之下 RT 與專科病患的占比下降。這是組合問題,單純推動了數學結果。在英國,如果你注意到,他們的量體很小、住院天數又很長,因此只要少數幾筆入院或出院,就會影響那個數字。所以在美國,純粹就是組合因素。而在英國,因為量體很小、住院天數又很高,所以不需要太多變動就會出現這種情況。我們在英國正改裝部分床位,以收治不同類型的病患;這類病患的住院天數相較美國會更長,但相較於英國整體平均則會更短。
Peter Heinz Costa - MD and Senior Analyst
Peter Heinz Costa - MD and Senior Analyst
I guess I see those as sort of the long-term trends that we've seen, but I'm trying to figure out why it would be so much of a change from Q1 to Q2, if there's anything in particular. There's -- and if it's not, is there a seasonal effect that I should be aware of that maybe we should think about going forward?
我想我把那些視為我們長期以來看到的趨勢,但我想弄清楚,為什麼從第一季到第二季會有這麼大的變化,是否有任何特別原因。如果沒有——那是否存在我需要留意的季節性因素,讓我們未來在推估時應該納入考量?
Joey A. Jacobs - Chairman & CEO
Joey A. Jacobs - Chairman & CEO
Well, the seasonal effect is that as you get towards the summer, the kids -- the child and adolescent population, there is more discharges there, and they're usually in the RTC facilities. So that would also impact it some, too. But there's nothing other than the mix of the acute beds as a percentage to the total beds here in the U.S. that's causing this to occur.
嗯,季節性因素是:接近夏季時,兒童與青少年族群的出院會增加,而他們通常在 RTC 機構。所以這也會帶來一些影響。但除此之外,沒有其他因素;主要就是在美國這邊,急性期床位占總床位的比例之組合變化,導致這個情況發生。
Operator
Operator
Now we'll take our next person from the queue, A.J. Rice from Crédit Suisse.
接下來我們將從等候隊列中請下一位提問者:Crédit Suisse 的 A.J. Rice。
Albert J. William Rice - Research Analyst
Albert J. William Rice - Research Analyst
First of all, just on the capital deployment, you mentioned your hope to have an acquisition announced in the third quarter, and you've also mentioned the JV opportunity a couple of times. Can you just sort of update us on the pipeline of -- are we talking about a larger deal in that acquisition? And then on the JV pipeline, what does that look like? And will that be a contributor to growth, you think next year?
首先,關於資本配置,你提到希望在第三季宣布一項收購,也提到合資(JV)機會好幾次。你能否更新一下案源管線——這次收購談的是較大型的交易嗎?另外在 JV 的案源管線方面,目前看起來如何?你認為它明年會成為成長的貢獻來源嗎?
Joey A. Jacobs - Chairman & CEO
Joey A. Jacobs - Chairman & CEO
A.J., the acquisitions are from a single facility to multi-facility. I think, most likely, it would be a single facility in the third quarter, acute facility that we would acquire in the third quarter. But there may be a comprehensive treatment center acquisition that would bring us more than one facility in the third quarter. So that's how the pipeline -- pipeline's strong. It's -- we go over it every Monday. Now on the joint ventures, absolutely, it's a big positive for us. And as you know, we opened up Erlanger in the second quarter. We've got Mount Carmel coming online. We've got a de novo in San Antonio coming online in the near future. So the joint venture opportunities are tremendous, and we have many negotiations, discussions going on. Actually, they took me out on one of those in the past 2 weeks to go meet with a joint venture -- potential joint venture partner. So we've got the University of Miami selecting its land to build the joint venture down there. So the joint venture front and the occasional de novo still look good. I would expect that we would do 3 to 5 joint ventures next year and somewhere around 2 to 3 de novos.
A.J.,收購案從單一機構到多機構都有。我認為第三季最有可能的是收購一家單一機構的急性期設施。但也可能會有一項綜合治療中心(comprehensive treatment center)的收購,讓我們在第三季一次取得不只一家機構。所以這就是管線的狀況——管線很強。我們每週一都會檢視。至於合資案,絕對是我們的一大正面動能。如各位所知,我們在第二季開出了 Erlanger。Mount Carmel 也即將上線。我們在聖安東尼奧的新設(de novo)也將在不久的將來上線。所以合資機會非常可觀,我們也有許多談判與討論正在進行。事實上,過去兩週他們還帶我去其中一個案子,與一位合資——潛在合資夥伴會面。另外,邁阿密大學正在選定土地,以在當地興建合資案。因此在合資面與偶爾的新設案方面,看起來仍然不錯。我預期明年我們會做3到5個合資案,以及約2到3個新設案。
Albert J. William Rice - Research Analyst
Albert J. William Rice - Research Analyst
Okay. And on -- my follow-up on the labor cost, you were up about 80 basis points. Professional fees was well contained, so maybe there wasn't much contract labor. I think that's more on that line. But can you just drill down a little bit more? Is this still mostly U.K.? Or are you seeing pressure in the U.S. as well? And what are you attributing it? Is it Brexit? Is it NHS moves or just the underlying market trend?
好的。另外——我對人力成本的追問:你們上升了大約80個基點。專業費用控制得很好,所以也許約聘人力不多。我想那更多反映在那一項。但你能否再更深入說明一下?這仍然主要是英國的因素嗎?還是你們在美國也看到壓力?你們把它歸因於什麼?是脫歐(Brexit)嗎?是 NHS 的措施,還是只是市場的基本趨勢?
Joey A. Jacobs - Chairman & CEO
Joey A. Jacobs - Chairman & CEO
Okay. Overall, the U.S. market is tight, but we're able to find the personnel to open up our beds and staff our facilities. So -- but it is tight here in the U.S. In the U.K, that is where there is more of the acute shortage, and it's all around immigration and allowing workers to enter the U.K. And Brexit, as you know, put many obstacles in place, but the NHS and the government both are working towards freeing that up. And right now, you can recruit nurses from the Commonwealth countries and bring them into the U.K., and we're working on that as we speak. The acute part of the labor shortage for the company is in the U.K. But here in the U.S., when you have labor market, when you have unemployment under 4%, there are certain labor markets that are tight.
好的。整體而言,美國市場確實偏緊,但我們仍能找到人員來開放床位並為我們的機構配置人力。所以——不過美國這邊確實緊。在英國,那裡的急性短缺更為明顯,主要與移民政策及允許勞工進入英國有關。而如你所知,脫歐設下了許多障礙,但 NHS 與政府都在努力朝放寬方向推進。目前你可以從英聯邦國家招募護理人員並引進英國,我們也正在進行這項工作。就公司而言,勞動力短缺最急迫的部分在英國。但在美國,當失業率低於4%時,某些勞動市場也會出現緊俏。
Operator
Operator
Our next question comes from Kevin Ellich from Craig-Hallum.
我們的下一個問題來自 Craig-Hallum 的 Kevin Ellich。
Kevin Kim Ellich - Senior Research Analyst
Kevin Kim Ellich - Senior Research Analyst
Joey, [last one it] talked about already, wondering if you could help us with the phasing of the remainder -- remaining beds, I think 524 for the back half. Will that be more weighted to Q3 or should we just spread it out evenly?
Joey,關於你剛才已經談到的最後一點,想請你協助我們了解剩餘部分的時程安排——我想下半年還有 524 張床位。這會比較偏重在第三季,還是我們應該把它平均分攤?
Joey A. Jacobs - Chairman & CEO
Joey A. Jacobs - Chairman & CEO
Once again, as we've seen for the past several years, the Q4 seems to be where we build the most beds. So -- and the timing of that is usually when a de novo or a big same-store project comes online. And we got several of those we're working on, so the timing of the completion really controls that. But within the next 6 months, we're going to have a lot of beds hopefully finish up.
再一次,就像過去幾年我們看到的一樣,第四季似乎是我們新增床位最多的時候。所以——而那個時間點通常是新設(de novo)或大型同店專案上線的時候。我們目前有好幾個這類專案在推進,因此完工時間點其實會主導這一切。不過在接下來 6 個月內,我們希望會有很多床位能夠完工。
Kevin Kim Ellich - Senior Research Analyst
Kevin Kim Ellich - Senior Research Analyst
Okay, that's helpful. And then just wondering if there has been any interesting changes or anything you guys have seen in the competitive landscape? Or has it pretty much stayed the same?
好的,這很有幫助。另外想請教,你們在競爭態勢上有沒有看到任何有趣的變化或新情況?還是基本上維持不變?
Joey A. Jacobs - Chairman & CEO
Joey A. Jacobs - Chairman & CEO
I think it's basically the same. We don't run into a lot of competition on the joint ventures. We run into none where we're doing the de novos. The acquisition that we're working on for the third quarter, the acute facility, there really wasn't any competition there with that transaction. They did have a banker, which kind of kept the process reasonable. So there's not been anybody new enter the market that I'm aware of that is a competitor. So it's basically the way it was. The first part of this year and last year, we are by far the consolidator in the market.
我認為基本上是一樣的。在合資案上我們不太會遇到很多競爭。在我們做新設(de novo)的地方則完全沒有競爭。我們正在推進、預計第三季完成的那筆收購——急性照護機構——那筆交易其實也沒有什麼競爭對手。他們確實有請投行顧問,這讓流程相對合理。所以就我所知,沒有任何新的競爭者進入市場。因此基本上還是原來的樣子。今年前半段以及去年,我們在市場上絕對是主要的整併者。
Operator
Operator
Next question comes from John Ransom from Raymond James.
下一個問題來自 Raymond James 的 John Ransom。
John Wilson Ransom - MD, Equity Research and Director of Healthcare Research
John Wilson Ransom - MD, Equity Research and Director of Healthcare Research
I had 3 quick ones. First of all, I assume, maybe this is wrong, but you're getting close to knowing what your kind of forward Medicaid rate looks like over the next 12 months. Are there any states that are still wrapping up budget cycles? Secondly, could you compare U.S. wage inflation today versus, say, 6 months to a year ago? And then thirdly, maybe you could remind us of the economics of these JVs and how long it takes them to get to profitability.
我有三個簡短問題。首先,我假設——也許我錯了——你們應該快要能掌握未來 12 個月的 Medicaid 前瞻費率大概會是什麼樣子。是否還有任何州仍在收尾其預算週期?第二,你能否比較一下目前美國的薪資通膨,與例如 6 個月到 1 年前相比的情況?第三,也請你提醒我們這些合資(JV)的經濟模式,以及通常需要多久才能達到獲利。
Joey A. Jacobs - Chairman & CEO
Joey A. Jacobs - Chairman & CEO
Okay. First, one, John, the Medicaid rate, states are still finishing up their budgets. We got some good increases this past year. The budget -- the state budgets still look good. The support for mental health still looks good. So once again, if we can get in that 2% to 3% range for Medicaid, we'll be pleased with that. As far as wage inflation, if you were talking to me this time last year, I was probably saying our budgets included a 2% wage inflation. This year, the budgets included a 3% wage inflation. And I think next year, we would probably budget around a 3% wage inflation for the labor force. And then on the joint ventures, our preferred model is an 80-20 joint venture. We own 80%, the other partner has 20%. We do have a 4% to 6% management fee that we get paid for providing management services to the facility, and then the earnings are prorated based on the 80-20. How? It varies a lot here. We've seen some of ours ramp up within 12 months and be breakeven after the end of 12 months. And really, the key starting time of tracking this is when you get your Medicare number. So you'll get your certificate of occupancy, but then it'll take you another 90 days, 120 days to get all your provider numbers. And once you get your provider numbers, usually, this ramping up of the census gets us to breakeven or profitable in 12 months. So that's how we see it, the model working.
好的。第一點,John,關於 Medicaid 費率,各州仍在完成他們的預算。我們在過去一年拿到了一些不錯的調升。州預算——各州的預算看起來仍然不錯。對心理健康的支持看起來也仍然不錯。所以再一次,如果 Medicaid 能落在 2% 到 3% 的調升區間,我們就會很滿意。至於薪資通膨,如果你在去年這個時候問我,我可能會說我們的預算包含 2% 的薪資通膨。今年的預算包含 3% 的薪資通膨。而我認為明年我們可能也會針對勞動力預算大約 3% 的薪資通膨。再來談合資,我們偏好的模式是 80/20 的合資。我們持有 80%,另一個合作夥伴持有 20%。我們會收取 4% 到 6% 的管理費,作為我們為機構提供管理服務的報酬,之後盈餘再依 80/20 比例分攤。多久?這差異很大。我們看過有些案子在 12 個月內就爬坡完成,並在 12 個月結束後達到損益兩平。而真正開始追蹤的關鍵起點,是你拿到 Medicare 編號的時候。你會先拿到使用執照(certificate of occupancy),但接著還需要再花 90 天、120 天去取得所有提供者編號。一旦拿到提供者編號,通常住院人數(census)的爬坡會讓我們在 12 個月內達到損益兩平或開始獲利。所以我們就是這樣看這個模式的運作。
John Wilson Ransom - MD, Equity Research and Director of Healthcare Research
John Wilson Ransom - MD, Equity Research and Director of Healthcare Research
And if I could just follow up, one of your competitors talked this week about one of the unexpected outcomes of IMD exclusion going away was that your hospital referrals are keeping more commercial patients and sending you more Medicaid patients. Are you seeing that?
我再追問一下,你們的一位競爭對手本週提到,IMD 排除條款取消後的一個意外結果是,醫院轉介端把更多商業保險病人留在院內,反而把更多 Medicaid 病人送到你們這邊。你們有看到這種情況嗎?
Joey A. Jacobs - Chairman & CEO
Joey A. Jacobs - Chairman & CEO
We don't see that at all. We don't see that at all. And quite frankly, maybe we're just lucky in that. Where our acute facilities are at, that's not occurring. And then on the Medicaid side, David Duckworth did an analysis looking at our Medicaid rates, and we have some very good, reasonable rates for the services we provide. So the Medicaid patient -- the incremental Medicaid patient to us is profitable.
我們完全沒有看到那種情況。我們完全沒有看到。坦白說,也許只是我們比較幸運。在我們急性照護機構所在的地區,並沒有發生那樣的事。另外在 Medicaid 方面,David Duckworth 做了一份分析,檢視我們的 Medicaid 費率;就我們提供的服務而言,我們有一些非常好、而且合理的費率。因此對我們來說,新增的 Medicaid 病人——邊際 Medicaid 病人是有利潤的。
Operator
Operator
Next question comes from Ryan Daniels from William Blair.
下一個問題來自 William Blair 的 Ryan Daniels。
Ryan Scott Daniels - Partner and Healthcare Analyst
Ryan Scott Daniels - Partner and Healthcare Analyst
Let me ask a quick one. With all the focus on the opioids legislation, can you give us an update on kind of what your thoughts are there for potential for increased funding? Number one. And then my follow-up would be, given the focus there, is that increasing M&A multiples in that space at all, given future hopes [of kind of] more volume and more treatment dollars flowing down?
我問一個簡短的。在各界都聚焦於類鴉片(opioids)立法的情況下,你能否更新一下你們對於潛在資金增加的看法?這是第一點。接著我的追問是,鑑於這個焦點,是否也在提高該領域的併購(M&A)倍數?畢竟市場對未來可能有更多量能、更多治療資金下沉流入抱有期待。
Joey A. Jacobs - Chairman & CEO
Joey A. Jacobs - Chairman & CEO
I think the consolidation of that space is still with the mom-and-pops, so the multiple pressures creep is not there. However, if you get to a company that has, say, more than 15 of these facilities, then they are going to want a higher multiple for that book of business, so -- now as far as legislation, it's all been positive. We have one large state that not only are they going to use their Cures money to expand it, but the state is actually going to use some of its money that it has because of the surpluses, and they're going to open the state up for this -- for the CTC or the MAT treatment centers. So we hope there'll be some other states that will follow that lead because this is a bellwether state that's doing this, where the governor is stepping up and putting money there. Now I was with a governor this past week in one of our states, and it was a meeting with him privately but then also in a larger population. And he very much talked about mental health and opiates and that -- what they needed to be doing to help save lives in that population. So Bryan Kaegi who heads up government affairs for us, it's -- right now, it's all positive for the states and the federal government and their support of increasing funding for the opiate patients.
我認為那個領域的整併仍主要發生在夫妻店/小型業者(mom-and-pops)之間,所以倍數上行的壓力並不明顯。不過,如果是一家擁有例如超過 15 家此類機構的公司,他們就會希望針對那本業務拿到更高的倍數;至於立法方面,目前整體都是正面的。我們有一個大型州不僅會用他們的 Cures 資金來擴張,該州也會因為有財政盈餘而動用部分自有資金,並且將州內對這項——對 CTC 或 MAT 治療中心——的開放程度提高。因此我們希望其他州也能跟進,因為這是一個具指標性的州(bellwether state),州長正挺身而出把資金投入在這裡。另外,我上週在我們其中一個州與州長會面,先是私下會談,之後也在更大的場合交流。他非常明確談到心理健康與類鴉片,以及他們需要做些什麼來幫助拯救該族群的生命。所以我們政府事務負責人 Bryan Kaegi——目前來看,無論是各州或聯邦政府,對於增加類鴉片病患相關資金的支持都是正向的。
Ryan Scott Daniels - Partner and Healthcare Analyst
Ryan Scott Daniels - Partner and Healthcare Analyst
Okay. And just a quick follow-up, given that specific funding in certain states, is there opportunities for you to look for de novo opportunities in the CTC space? Or is that really more of an area where you just do a tuck-in deal and expand capacity that way if you saw an opportunity?
好的。再快速追問一下,鑑於某些州有特定資金支持,你們是否有機會在 CTC 領域評估新設(de novo)機會?還是說那更像是一個你們只會做補強式(tuck-in)交易、並透過那種方式擴充產能的領域——如果你們看到機會的話?
Joey A. Jacobs - Chairman & CEO
Joey A. Jacobs - Chairman & CEO
No, Ryan. We do 4 to 6 de novos in that space every year. Now this bellwether state may give us the opportunity with our other de novos that we'll have mid-double-digit number of facilities come online next year. So -- and then there is the tuck-in acquisitions that Steve and his -- Steve Davidson and his department work on, but we could have double-digit de novos just on our own next year.
不,Ryan。我們在那個領域每年會做4到6個新設(de novo)。現在這個指標性州可能會讓我們有機會,連同其他我們正在推進的新設案,明年將有中雙位數數量的機構投入營運。所以——另外還有Steve以及他——Steve Davidson和他的部門在做的補強式併購(tuck-in acquisitions),但光靠我們自己,明年也可能就有雙位數的新設案。
Operator
Operator
Next question comes from Kevin Fischbeck from Bank of America.
下一個問題來自美國銀行(Bank of America)的Kevin Fischbeck。
Kevin Mark Fischbeck - MD in Equity Research
Kevin Mark Fischbeck - MD in Equity Research
Wanted to follow up on some of the labor cost comments. I guess you guys are talking about 3% wage inflation, but your rate per day was kind of above that number this quarter, and we still saw some margin pressure. So what do you think the same-store revenue growth has to be in order for you guys to maintain margins given this labor backdrop?
我想追問一下你們對人力成本的一些評論。我猜你們談的是3%的薪資通膨,但你們本季的每日費率(rate per day)似乎高於那個數字,而我們仍然看到一些利潤率壓力。所以在這樣的人力背景下,你們認為同店營收成長需要到什麼程度,才能維持利潤率?
Joey A. Jacobs - Chairman & CEO
Joey A. Jacobs - Chairman & CEO
Well, a little bit in the U.S. Kevin, I'm sure you recognize that the second quarter margin last year was the highest margin we've ever had, and we got close to it again at 28.1%. So even though it was down slightly, it's going up against the highest margins that we've seen. Obviously, you would like to have 200 basis points in between the revenue growth and the expense growth and let as much of that possible flow to the EBITDA margin, which would be accretive earnings to us internally. So if we can get a 200 spread or 100 basis point spread between those 2 numbers, I think that maintains and improves the margin.
Kevin,在美國這邊,我相信你也知道,去年第二季的利潤率是我們有史以來最高的,而我們這次又接近那個水準,達到28.1%。所以即使略有下滑,也是因為對比的是我們見過的最高利潤率。顯然,你會希望營收成長與費用成長之間能有200個基點的差距,並讓其中盡可能多的部分流向EBITDA利潤率,這對我們內部而言就是增厚獲利。所以如果我們能在這兩個數字之間拉出200個基點、或至少100個基點的差距,我認為就能維持並改善利潤率。
Kevin Mark Fischbeck - MD in Equity Research
Kevin Mark Fischbeck - MD in Equity Research
Okay. And I think last quarter, you mentioned a goal in the U.K. of kind of getting the labor costs down to 64% of revenue from 65% in Q4. Is that still the target or are kind of the things you're seeing now make that more difficult to get to? And then I guess maybe based or following up on that, in the past, you've seen labor shortages restrict growth. Do you expect that to happen? Or is this really more about you can find them, you just have to pay up for them?
好的。另外我記得上季你們提到英國的目標,是把人力成本占營收比重從第四季的65%降到64%。這仍然是目標嗎?還是你們現在看到的情況讓達成更困難?然後我想也順著追問,過去你們曾因人力短缺而限制成長。你們預期會再發生嗎?還是其實比較像是人找得到,只是必須付更高的薪資?
Joey A. Jacobs - Chairman & CEO
Joey A. Jacobs - Chairman & CEO
It's more of the latter and that we are working as hard as we can to get to that 64% number. And by no means have we given up on that as a goal for this year. And we met with our U.K. people, our team from the U.K. last week, and there's a lot of effort being put on achieving that goal. But however, if we've got -- if the NHS comes to us and wants us to build 20 beds for our CAMs unit, which is a needed service and one of our higher reimbursement services, if we have to use more agency expense to get those beds online, we're going to do that knowing that long term, we're going to be creating our own staffing, and that cost will eventually go away.
比較偏向後者;而且我們正盡最大努力達到64%這個數字。我們絕對沒有放棄把它當作今年目標。我們上週與英國同仁、英國團隊開會,大家正投入大量努力來達成這個目標。不過,如果NHS來找我們,希望我們為CAMs單位增建20張床位——這是必要的服務,也是我們報銷較高的服務之一——若我們必須用更多派遣人力(agency)費用來讓這些床位上線,我們也會這麼做,因為我們知道長期而言我們會建立自己的編制人力,而那項成本最終會消失。
Operator
Operator
We'll take our next question from Ralph Giacobbe from Citi.
我們下一個問題來自花旗(Citi)的Ralph Giacobbe。
Ralph Giacobbe - Director
Ralph Giacobbe - Director
I guess, first, just the lower guidance all related -- was it all related to FX and interest costs? Or were there other sort of operational tweaks such as -- we've been talking a lot about sort of the continued labor cost pressures. And then maybe just give some details on some of the back half assumptions for the U.S. and U.K. both in terms of volume pricing if you could and just the confidence on the cost side to get back to sort of the implied -- what implies sort of a 6% EBITDA growth from the low single digit that you saw this quarter.
我想先問一下,下修指引是否全部都與匯率(FX)和利息成本有關?還是還有其他營運面的調整,例如——我們一直談到持續的人力成本壓力。另外,如果可以的話,能否提供一些下半年對美國與英國的假設細節,包括量與價?以及在成本端回到某種隱含——也就是從本季看到的低個位數,回到隱含約6% EBITDA成長——你們的信心如何?
Joey A. Jacobs - Chairman & CEO
Joey A. Jacobs - Chairman & CEO
Well, there was a lot in that question. First, let's deal with the guidance. The guidance change was only for the FX. Originally, starting out the year, we had it at 1.35, and we're adjusting that for the last 6 months to be 1.30, which reflects basically what -- where it's at today, maybe slightly higher, might be 1.31 today, but that is the FX. And then the interest expense, interest rates have risen. There's a possibility that there might be another rate hike in the last 6 months. And we wanted to reforecast that last 6 months for the interest expense, so the guidance was only impacted by those 2 items, period. And the other part of your question was...
這個問題涵蓋很多。先談指引。指引的變動只與匯率有關。年初我們原本用1.35,現在把最後6個月調整為1.30,基本上反映目前的水準——今天可能略高一些,也許是1.31——但這就是匯率因素。再來是利息費用,利率已經上升。最後6個月仍有可能再升息一次。我們希望重新預測最後6個月的利息費用,所以指引只受到這兩項影響,就這樣。你問題的另一部分是……
Ralph Giacobbe - Director
Ralph Giacobbe - Director
Just the back half assumptions.
就是下半年的假設。
Joey A. Jacobs - Chairman & CEO
Joey A. Jacobs - Chairman & CEO
Back half assumptions. Now as I stated earlier, I very much want the U.S. to get into the 2% patient day growth, maybe even 3% patient day growth as we bring these beds online and get them staffed up and ready to go. So that's our goal there. Now the U.K. numbers for the second quarter on revenue growth and patient day, I think it's the best they've had in a long time, and that's coming off a better first quarter. So all we would want them to do there is to continue to chip away and improve those numbers. So -- and hopefully, we would find and they would find a way to manage the agency expense better. So those would be our expectations.
下半年的假設。如我先前所說,我非常希望美國能達到2%的病人日(patient day)成長,甚至在我們讓這些床位上線、完成配置人力並準備就緒後,能到3%的病人日成長。所以那是我們的目標。至於英國,第二季在營收成長與病人日方面的數字,我認為是他們很長一段時間以來最好的表現,而且是在第一季已經更好的基礎上。所以我們希望他們持續一點一滴地改善這些數字。並且希望我們能找到、他們也能找到更好的方式來管理派遣人力(agency)費用。這些就是我們的預期。
Ralph Giacobbe - Director
Ralph Giacobbe - Director
Okay, that's helpful. If I could squeeze in one more, length of stay, we've talked about it a little bit. You attribute it to sort of mix changes. Didn't really hear you talk much about pressures from managed Medicaid or insurers squeezing on days. So are you seeing any of those types of pressures? And then just related to that, why is the decline in the length of stay significantly worse in the non-same-store base?
好的,這很有幫助。如果我可以再塞一個問題,關於住院天數(length of stay),我們稍微談過。你們把它歸因於組合(mix)變化。我沒有太聽到你們談到管理式Medicaid或保險公司在天數上施壓、壓縮住院日。所以你們有看到這類壓力嗎?另外也相關的是,為什麼非同店(non-same-store)基礎的住院天數下滑明顯更嚴重?
Joey A. Jacobs - Chairman & CEO
Joey A. Jacobs - Chairman & CEO
The non-same-store base, I have not looked at it that way, but I have a feeling because of the few facilities that are in those numbers and that they are ramping up and they're mainly de novo joint ventures, that small number movements probably are impacting those more than the big base of the same-store numbers, whether you have it here or in the U.K. And once again, in the U.S., it's just a mix. The length of stay is still very stable, similar to what it was for the past several years. And then in the U.K., the numbers are so small, it doesn't take many admissions or discharges to impact those numbers on the length of stay. And we are building some services there where the NHS has come to us and asked us to add services that would have a somewhat shorter length of stay, but it's a service that's needed and something we specialize in.
非同店那一塊,我沒有用那種方式去看,但我有種感覺是,因為納入那些數字的機構數量不多,而且它們正在爬坡期,主要是新設的合資(de novo joint ventures),因此小幅的數量變動,對它們的影響可能比對同店的大基數影響更大,不論是在美國或英國都是如此。而且再說一次,在美國這只是組合因素。住院天數仍然非常穩定,和過去幾年差不多。至於英國,數字基數很小,不需要太多入院或出院就會影響住院天數的數據。我們也正在那邊建立一些服務,NHS來找我們要求新增的服務,其住院天數會相對較短,但這是有需求的服務,也是我們擅長的領域。
Operator
Operator
Next question comes from Frank Morgan from RBC Capital Markets.
下一個問題來自RBC資本市場(RBC Capital Markets)的Frank Morgan。
Frank George Morgan - MD of Healthcare Services Equity Research
Frank George Morgan - MD of Healthcare Services Equity Research
I wanted to go back to the rate growth again. And obviously, there were discussions around the change in the mix of patients. So I'm just curious, between actual real rate increases versus the mix issue here, could you kind of break that out into the components? And then how much more remaining mix shift -- presumably, I think you were meaning by that more of the acute side versus the RTC. Like, where are you now? Where do you think that the positive effect of the mix shift will settle out in terms of rate growth? That's my first question.
我想再回到費率成長(rate growth)這個議題。顯然,大家討論過病患組合變化。所以我想了解,在實際的真實費率上調與組合因素之間,你能否把它拆解成不同組成?另外,剩餘還會有多少組合轉移——我猜你指的是急性端(acute)相對於RTC那一端——你們現在在哪裡?你們認為組合轉移對費率成長的正面效果,最終會落在什麼水準?這是我的第一個問題。
Joey A. Jacobs - Chairman & CEO
Joey A. Jacobs - Chairman & CEO
Okay. Frank, well, now you've just stumped me. I've been able to answer all the questions, but this detail really lies with David. So I'm going to ask David to give you the answers here.
好的。Frank,嗯,你這下可把我難倒了。我一直都能回答所有問題,但這個細節真的要由David來說明。所以我會請David在這裡給你答案。
David M. Duckworth - CFO, CAO & Controller
David M. Duckworth - CFO, CAO & Controller
Yes. And Frank, there is some service mix that is a positive to our rate growth as we do see acute growth become more significant for the company. I would say the effect of that on rate is very small. And as we look at the rate growth by service line, we are seeing a very similar rate growth in that 3% range. So seeing good rate increases as you look at it by service line and in total. And then outpatient, the revenue growth that we see from our CTC business, which is part of the mix effect, has also been very positive for the company.
是的。而且Frank,隨著我們看到急性照護的成長對公司變得更為顯著,服務組合中確實有一些因素對我們的費率成長是正面的。我會說它對費率的影響非常小。而當我們按服務線來看費率成長時,我們看到非常相近的費率成長,大約在3%的區間。所以不論按服務線或整體來看,都能看到不錯的費率上調。另外,門診方面,我們從CTC業務看到的營收成長(這也是組合效應的一部分)對公司也非常正面。
Frank George Morgan - MD of Healthcare Services Equity Research
Frank George Morgan - MD of Healthcare Services Equity Research
Got you. And since I've got the CFO, I'll ask you a question. In light of the fact that rates are rising, do you have any plans to either try to hedge that debt or do anything to reduce your exposure to rate increases? And I'll hop off.
了解。既然CFO在,我再問一個問題。鑑於利率正在上升,你們是否有任何計畫要對該債務進行避險,或採取任何措施來降低你們對利率上升的曝險?我問完就先下線。
David M. Duckworth - CFO, CAO & Controller
David M. Duckworth - CFO, CAO & Controller
Well, it's a conversation we have, of course, historically had. The variable rates that we have had have been very positive for the company in the last few years. As we think about hedging our exposure there, we do look at the effect of that and the immediate step-up in our interest expense associated with that. Right now, we don't think there's a significant benefit to have an immediate step-up in our interest expense in order to lock in a fixed rate. That is a conversation that we have periodically, but right now, we don't think that makes sense based on the economic analysis of that.
嗯,這當然是我們一直以來都有在討論的議題。過去幾年,我們的浮動利率部位對公司非常有利。當我們考慮對該曝險進行避險時,也會評估其影響,以及因此帶來的利息費用立即上升。目前我們不認為,為了鎖定固定利率而讓利息費用立刻跳升,會帶來顯著的好處。這是我們會定期討論的議題,但就目前而言,基於相關的經濟分析,我們認為這樣做並不合理。
Operator
Operator
Next question comes from Anagha Gupte from Leerink Partners.
下一個問題來自Leerink Partners的Anagha Gupte。
Anagha A. Gupte - MD, Healthcare Services and Senior Research Analyst
Anagha A. Gupte - MD, Healthcare Services and Senior Research Analyst
So going to the U.K. again, the recovery that you're seeing on your admissions growth, how much of this is because you're repurposing your addiction and eating disorder beds to the child and adolescent? And is that the strategy going forward? Or is there going to still that pent-up demand that you talked about when the NHS changed their referral process and decentralized it more to the primary care trusts?
再回到英國,你們看到住院量成長的復甦,其中有多少是因為你們把成癮與飲食失調的床位重新配置到兒童與青少年?這會是未來的策略嗎?還是說,當NHS改變轉介流程、把權限更下放到基層照護信託(primary care trusts)時,你們提到的那股被壓抑的需求仍會存在?
Joey A. Jacobs - Chairman & CEO
Joey A. Jacobs - Chairman & CEO
I think where we're doing -- these -- the changing of the mix there is one-off requests from the NHS, that the other pieces of the business continue to have demand and need services. So it's more a one-off really where we're retrofitting the service line, and that is due to the request from the NHS, and we try to be a good partner with them. And the reason we do that is that the NHS looks for a continuum of care. And if we can be their full continuum of care, we think that positions us very well in not only taking care of the patient and getting a positive outcome, but the patient -- they know that when the patient comes to our facilities that we're able to take them all the way to the end to be discharged. So -- but many a time -- most of the time when we're retrofitting, it's a request from the NHS or there's such a demand in services for that area that we would do it also ourselves.
我認為我們在做的——這些組合的調整——是NHS一次性的要求;而業務的其他部分仍然有需求、也需要服務。所以這真的比較像一次性的情況:我們在改造服務線,這是因應NHS的要求,我們也希望成為他們的良好合作夥伴。我們之所以這麼做,是因為NHS希望有一個連續性的照護體系。如果我們能提供完整的連續性照護,我們認為這不僅能讓我們在照顧病患並取得正向結果方面處於非常有利的位置,而且病患——他們也知道,當病患來到我們的機構時,我們能一路照護到最後、直到出院。所以——但很多時候——大多數時候我們進行改造,是因為NHS提出要求;或者該領域的服務需求非常強,我們也會自行進行。
Anagha A. Gupte - MD, Healthcare Services and Senior Research Analyst
Anagha A. Gupte - MD, Healthcare Services and Senior Research Analyst
Got it, okay. So -- but is there any expectation of that pent-up demand resuming at some point? Are these untreated patients sitting there waiting for treatment? And will the NHS change their stance toward admissions? And will you build out additional beds in that case to reap -- or to get that?
了解,好的。那——是否預期那股被壓抑的需求在某個時間點會回來?是否有一些未治療的病患正在等待治療?NHS會改變他們對收治入院的立場嗎?如果是的話,你們會擴建更多床位來把握——或取得——那些需求嗎?
Joey A. Jacobs - Chairman & CEO
Joey A. Jacobs - Chairman & CEO
We are pretty much -- we're not guaranteed, but we have high confidence in that if we retrofit a service for the NHS, that we have confidence that they are going to give us the patients to fill up that facility.
我們基本上——雖然不是保證,但我們非常有信心:如果我們為NHS改造一項服務,我們有信心他們會把病患交給我們,來填滿那個機構。
Anagha A. Gupte - MD, Healthcare Services and Senior Research Analyst
Anagha A. Gupte - MD, Healthcare Services and Senior Research Analyst
And then on revenue per patient day, which looked really good at 3.9%, is that, again, more of a mix effect just given the pressures with Brexit and everything?
另外,關於每病患日營收(revenue per patient day),看起來3.9%非常不錯;這是否同樣主要是組合效應,考量到Brexit等各種壓力?
Joey A. Jacobs - Chairman & CEO
Joey A. Jacobs - Chairman & CEO
It is a little -- it is mix, but it's also our people have done a very good job at the local level in the U.K. in negotiating rates, so that is very positive there, too. So it's a combination of both of those.
有一點——是組合因素,但同時也是我們在英國當地的團隊在談判費率方面做得非常好,所以那也非常正面。因此是兩者的綜合。
Anagha A. Gupte - MD, Healthcare Services and Senior Research Analyst
Anagha A. Gupte - MD, Healthcare Services and Senior Research Analyst
And as far as the labor contract, which, as I understand, was implemented on April 1, so is that included in the second half, I'm assuming, of guidance? And does that pressure escalate into '19 and '20 given it's a 3-year contract?
至於勞動合約,據我了解是4月1日開始實施,所以我猜這已經包含在下半年指引裡?而且由於這是三年期合約,這種壓力在2019與2020年會加劇嗎?
Joey A. Jacobs - Chairman & CEO
Joey A. Jacobs - Chairman & CEO
I'm going to have to defer to David again on this answer.
這個回答我得再請David來說明。
David M. Duckworth - CFO, CAO & Controller
David M. Duckworth - CFO, CAO & Controller
Well, there is a contract, not between our company and our employees, that's more on the NHS employee side. So no, that does not directly impact us in the second half of the year. We do have pay increases with our employees that we have given annually that is factored into our projections for the remainder of the year as well as 2019.
嗯,確實有一份合約,但不是我們公司與員工之間的合約,那比較是NHS員工端的合約。所以不會在今年下半年直接影響我們。我們確實每年都會給員工加薪,這已經納入我們對今年剩餘期間以及2019年的預估之中。
Operator
Operator
We'll take the next question from Matthew Gillmor from Robert Baird.
下一個問題由Robert Baird的Matthew Gillmor提問。
Matthew Dale Gillmor - Senior Research Analyst
Matthew Dale Gillmor - Senior Research Analyst
One more on the U.K. labor issues. Joey mentioned Brexit and immigration barriers as some of the macro factors. What impact does the exchange rate itself have on labor supply in terms of clinicians being willing to come to the U.K.? And how important is that in terms of improving the labor issues?
再追問一個英國勞動力議題。Joey提到Brexit與移民障礙是一些總體因素。匯率本身對勞動供給有什麼影響,例如臨床人員是否願意到英國工作?而這在改善勞動力問題上有多重要?
Joey A. Jacobs - Chairman & CEO
Joey A. Jacobs - Chairman & CEO
Well, obviously, for the continent there, the lower value of the pound hurts them coming to the U.K. Now as I mentioned earlier in my comments, we see the Commonwealth countries are going to be a possible solution to our labor mix there because they have opened up the barriers for them to come to the U.K. So we're optimistic about that. Now there will be -- if the Brexit was removed or the immigration barriers were removed, naturally, there's some Europeans that would rather work in the U.K., independent of what the pound level is. So -- but the pound level can hurt you on having the employees from the continent come in.
嗯,很明顯地,對歐洲大陸那邊而言,英鎊走弱會降低他們來英國工作的吸引力。如同我先前在評論中提到的,我們認為英聯邦國家可能會成為我們當地人力組合的一個解方,因為他們來英國的障礙已經被放寬。所以我們對此感到樂觀。
Matthew Dale Gillmor - Senior Research Analyst
Matthew Dale Gillmor - Senior Research Analyst
Okay. And then one on the JV pipeline. I was curious if you could characterize that in terms of the activity level you're seeing from -- for smaller systems with 1 to 2 hospitals versus large systems like Ascension. And are those larger systems typically looking for a JV partner in a single market? Or do those relationships contemplate sort of multiple JVs in multiple markets over time?
好的。再問一個關於合資(JV)案源管線的問題。我想請你們描述一下你們看到的活動程度:是來自只有1到2家醫院的小型體系比較多,還是像Ascension這樣的大型體系比較多?而那些大型體系通常是在單一市場尋找合資夥伴嗎?還是這類關係會考量隨時間在多個市場進行多個合資?
Joey A. Jacobs - Chairman & CEO
Joey A. Jacobs - Chairman & CEO
We are having discussions with all sizes of systems. And on the larger systems, I think what you would do is get a joint venture started with them. And if it goes well, then I think you might -- could become their preferred joint venture partner throughout their system, which would give you more opportunities to do more deals with that one system.
我們正在與各種規模的體系進行討論。至於大型體系,我認為你會先與他們啟動一個合資。如果進展順利,那麼你可能——也有機會成為他們整個體系的優先合資夥伴,這將讓你有更多機會與同一個體系做更多交易。
Operator
Operator
Next question comes from Dana Hambly from Stephens.
下一個問題來自 Stephens 的 Dana Hambly。
Dana Rolfson Hambly - Research Analyst
Dana Rolfson Hambly - Research Analyst
Just to follow up on the U.K. pricing, because the number was so high, I'm just wondering if that's a good number to be using into the second half of the year. Should we temper expectations there?
我想追問一下英國的定價,因為這個數字非常高,我只是想知道把它用在今年下半年是否合適。我們是否應該在那裡降低一些預期?
David M. Duckworth - CFO, CAO & Controller
David M. Duckworth - CFO, CAO & Controller
Dana, I think -- this is David. I do think that is a number that we expect for the second half of the year. And again, it reflects rate increases that we have already seen and continue to see, as well as the service mix where we are growing more in health care than we are in some of the other service lines. So that is an expectation we have for the year.
Dana,我想——我是 David。我確實認為這是我們對今年下半年的預期數字。再說一次,它反映了我們已經看到且仍在持續看到的費率上調,以及服務組合的變化——我們在醫療保健領域的成長高於其他一些服務線。所以這是我們對今年的預期。
Dana Rolfson Hambly - Research Analyst
Dana Rolfson Hambly - Research Analyst
That's helpful. And then, Joey, you mentioned in the U.S. in the same store that there are some issues that some facilities -- I think you mentioned in the first quarter a handful of facilities that were dragging on growth as well. And just curious, are we talking about the same group of facilities? Or are there newer facilities with newer issues that popped up in the second quarter?
這很有幫助。然後,Joey,你提到在美國同店方面,有一些問題是某些機構——我記得你在第一季提到有少數幾家機構也在拖累成長。我只是好奇,我們談的是同一批機構嗎?還是第二季又出現了新的機構、帶來新的問題?
Joey A. Jacobs - Chairman & CEO
Joey A. Jacobs - Chairman & CEO
We're still talking about the same group, but the number of those facilities is getting much smaller.
我們仍然在談同一批,但這些機構的數量正在大幅減少。
Dana Rolfson Hambly - Research Analyst
Dana Rolfson Hambly - Research Analyst
Okay, that's helpful. Last one for me. I just -- on construction costs, have you seen a material uptick in construction costs in the last, call it, year?
好的,這很有幫助。我最後一個問題。我想問——關於建造成本,在過去大概一年左右,你們是否看到建造成本有明顯上升?
Joey A. Jacobs - Chairman & CEO
Joey A. Jacobs - Chairman & CEO
Well, there's no doubt that construction costs across the country have gone up. I think now we're using around $250,000 per same-store bed. And in some places, we can do it less, but in some places, it's more than that. I can tell you that an 80-bed hospital all-in, land, construction costs usually costs somewhere in the low $30 million range for a brand-new facility. So I do know that cost range.
嗯,毫無疑問,全國的建造成本都上升了。我想我們現在同店每張床位大約以 25 萬美元來估算。有些地方我們可以做得更低,但有些地方會高於這個數字。我可以告訴你,一家 80 床的醫院,包含土地與建造等全部成本,一個全新設施通常大約在 3,000 萬美元出頭的區間。所以我確實了解那個成本範圍。
Operator
Operator
Next question comes from Ann Hynes from Mizuho Securities.
下一個問題來自 Mizuho Securities 的 Ann Hynes。
Ann Kathleen Hynes - MD of Americas Research
Ann Kathleen Hynes - MD of Americas Research
So just to get back to the second half of the guidance ramp, so just to clarify, you think that if you can get that U.S. same-store patient day growth back to 2% to 3% plus control labor, you think you can kind of reach that mid- to high single-digit EBITDA that's implied in guidance?
我想回到指引在下半年的爬坡部分,確認一下:你們認為如果能把美國同店病人日成長拉回到 2% 到 3% 以上,同時控制人力成本,你們就能達到指引所隱含的 EBITDA 中到高個位數成長,是嗎?
Joey A. Jacobs - Chairman & CEO
Joey A. Jacobs - Chairman & CEO
Yes.
是的。
Ann Kathleen Hynes - MD of Americas Research
Ann Kathleen Hynes - MD of Americas Research
And the past couple of years, Q3 has been a rough quarter for you, and I know a lot of it has to do with seasonality. Do you think guidance fully reflects the seasonality, especially in the U.K.? Are you comfortable with your assumptions going into the summer months?
而且過去幾年,第三季對你們來說一直是比較艱難的一季,我知道很大一部分與季節性有關。你認為指引已充分反映季節性了嗎,尤其是在英國?對於進入夏季月份的假設,你們有把握嗎?
Joey A. Jacobs - Chairman & CEO
Joey A. Jacobs - Chairman & CEO
Ann, that's -- I wish I had that answer. We think we've done the best we can at looking at the third quarter and trying to make sure that our operations deliver on the third quarter. We had a little bit of that concern in the second quarter, that there were some that still didn't believe how the employment tax issue worked, in that how can you increase your earnings per share from the first quarter to second quarter? And we did that. So we've got our fingers crossed. We look at the census every day, and Ann, we don't know what August is going to bring us yet, but I'm hopeful that operations will have a terrific third quarter.
Ann,這個——我希望我有答案。我們認為我們已盡最大努力去檢視第三季,並確保我們的營運能在第三季交付成果。第二季我們也有一點這方面的擔憂,因為仍有人不相信就業稅問題的運作方式——也就是你怎麼可能從第一季到第二季提高每股盈餘?而我們做到了。所以我們只能祈禱一切順利。我們每天都在看住院人數(census),Ann,我們還不知道八月會帶來什麼,但我希望營運能在第三季表現非常出色。
Operator
Operator
Next question comes from John Ransom from Raymond James.
下一個問題來自 Raymond James 的 John Ransom。
John Wilson Ransom - MD, Equity Research and Director of Healthcare Research
John Wilson Ransom - MD, Equity Research and Director of Healthcare Research
So this is a numbers question. So Joey, you can just beg this one off, and I'm going to go to my man David. The new beds that came online, is there any way to think about second half contribution versus first half -- is that -- in terms of a potential tailwind?
這是一個數字問題。Joey,你可以先略過這題,我要把問題交給我的老兄 David。新投入營運的床位,有沒有什麼方式可以思考下半年相對於上半年的貢獻——也就是說,是否可能形成一個順風?
David M. Duckworth - CFO, CAO & Controller
David M. Duckworth - CFO, CAO & Controller
Yes, we do think about that. The 4 new facilities that we've opened since the fourth quarter are a drag on our second quarter numbers. We do think the ones that opened in the fourth quarter will start to improve over the second half of the year, but we did have one very recent opening in June. So at this point, we have some new facilities that are making great progress, but we also have some new facilities coming online. But I think those as a group will improve over the second half of the year.
是的,我們確實會這樣思考。自第四季以來我們新開的 4 家新機構,對我們第二季的數字是個拖累。我們確實認為第四季開業的那些會在今年下半年開始改善,但我們在六月也有一家非常近期的新開業。所以目前我們有一些新機構進展非常好,但同時也有一些新機構正在投入營運。但我認為整體而言,這一組在下半年會改善。
John Wilson Ransom - MD, Equity Research and Director of Healthcare Research
John Wilson Ransom - MD, Equity Research and Director of Healthcare Research
Would you guys ever consider, as you get more of these, just breaking out your novo losses? I know some companies do that. That might be helpful.
你們是否曾考慮過,隨著這類項目變多,把你們的 novo 虧損單獨揭露出來?我知道有些公司會這麼做。那可能會有幫助。
Joey A. Jacobs - Chairman & CEO
Joey A. Jacobs - Chairman & CEO
John, we'll take that under advisement for 2019, absolutely.
John,我們會把這個建議納入考量,作為 2019 年的規劃之一,當然。
Operator
Operator
This concludes the question-and-answer session. Now I would like to turn the call back to Mr. Jacobs for any additional or closing remarks.
問答環節到此結束。現在我想把電話交回 Jacobs 先生,請他做任何補充或結語。
Joey A. Jacobs - Chairman & CEO
Joey A. Jacobs - Chairman & CEO
Thank you, operator. Thank you all for showing your interest in Acadia. We had a great second quarter. We did hit our numbers, so very pleased about that. The operations team throughout the company worked very, very hard. And then also, the opportunity before us to continue to grow this company and make acquisitions and hit all our metrics is there for us, we've just got the job to do. So once again, thank you for listening in, and we'll see you again on the third quarter call.
謝謝你,接線員。也謝謝各位對 Acadia 的關注。我們第二季表現很棒。我們確實達成了我們的數字,因此對此非常滿意。公司各地的營運團隊都非常、非常努力。此外,擺在我們面前的機會——持續成長這家公司、進行併購並達成所有指標——都在那裡,我們只需要把工作做好。所以再次感謝各位收聽,我們第三季電話會議再見。
Operator
Operator
Thank you. Ladies and gentlemen, that will conclude today's conference call. Thank you for your participation. You may now disconnect.
謝謝。各位女士、先生,今天的電話會議到此結束。感謝各位的參與。您現在可以掛線。